12:00 AM
 | 
Jan 11, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Vinorelbine emulsion regulatory update

Adventrx submitted an NDA to FDA for ANX-530 to treat non-small cell lung cancer (NSCLC). The NDA was submitted...

Read the full 71 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >